Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

FDA Extends PDUFA Date for BLA/sNDA of Ublituximab Plus Umbralisib in CLL/SLL

March 3rd 2022

The FDA has extended the Prescription Drug User Fee Act goal date for the biologics license application and supplemental new drug application seeking the approval of ublituximab plus umbralisib in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Dr. Burger on the Current Landscape of CAR T-Cell Therapy in CLL

March 1st 2022

Jan A. Burger, MD, PhD, discusses the current landscape of CAR T-cell therapy in chronic lymphocytic leukemia.

Dr. Oh on the Evolving Treatment Landscape in CLL

February 24th 2022

Stephen Oh, MD, PhD, discuses the evolving treatment landscape of chronic lymphocytic leukemia.

Dr. Kahl on the Potential of Zanubrutinib in the Frontline Treatment of CLL

February 24th 2022

Brad S. Kahl, MD, discusses the potential for zanubrutinib in the frontline treatment of chronic lymphocytic leukemia.

Zanubrutinib Applications for CLL and MZL Accepted for Review in Europe

February 23rd 2022

The European Medicines Agency has accepted for review 2 new indication applications for zanubrutinib as a therapeutic option for patients with chronic lymphocytic leukemia and for those with marginal zone lymphoma.

FDA Accepts sNDA for Zanubrutinib in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

February 23rd 2022

The FDA has accepted for review a supplemental new drug application for zanubrutinib for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Treating CLL With Anti-CD20 Antibody Regimens

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Q and A Session

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, answer audience questions regarding CLL and BTK inhibitors during a question & answer session.

Selecting Treatment for CLL and Managing BTK Inhibitor-Associated Toxicities

February 18th 2022

Two experts discuss their approach to selecting therapy for patients with CLL and provide insight on managing adverse events when using BTK inhibitors.

Chronic Lymphocytic Leukemia and BTK Inhibitors

February 18th 2022

Amy Goodrich, RN, MSN, CRNP, and Kirollos S. Hanna, PharmD, BCPS, BCOP, provide an overview of chronic lymphocytic leukemia (CLL) and the role BTK inhibitors play in treatment.

Clinical Implications Continued

February 18th 2022

Dr Lamanna expands on BTK clinical implications within CLL therapy.

Dr. Burger on the Changing Treatment Landscape of CLL

February 17th 2022

Jan A. Burger, MD, PhD, discusses the changing treatment landscape of chronic lymphocytic leukemia.

Dr. Choi on the Addition of Ublituximab to Ibrutinib in R/R CLL

February 16th 2022

Michael Choi, MD, discusses the results of the phase 3 GENUINE trial examining ublituximab in combination with ibrutinib vs ibrutinib alone in patients with relapsed/refractory chronic lymphocytic leukemia.

Fixed-Duration Therapy in Relapsed/Refractory CLL: Ibrutinib Plus Venetoclax

February 14th 2022

Considerations for treating patients with relapsed/refractory chronic lymphocytic leukemia with the combination of ibrutinib and venetoclax.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Clinical Implications of BTK Inhibitors in CLL

February 11th 2022

Dr Shah explains the clinical implications of using BTK inhibitors for CLL treatment.

Non-Covalent BTK Inhibitors

February 11th 2022

Dr Shah introduces non-covalent BTK inhibitors and clinical findings from their use in the CLL landscape.